Maze Therapeutics, Inc. (MAZE) Discuses On MZE782 Phase 1 Healthy Volunteer Trial Results Call (Transcript)

Core Viewpoint - Maze is presenting data from the Phase I clinical trial of MZE782, an oral SLC6A19 inhibitor aimed at treating phenylketonuria (PKU) in patients with chronic kidney disease (CKD) [1] Group 1 - The event is intended for the investment community and includes forward-looking statements based on current expectations [2] - Management's statements involve assumptions, risks, and uncertainties, with no obligation to update or revise these statements [2] - The presentation will feature introductory remarks from the CEO, followed by a review of Phase I clinical data by the Chief Medical Officer [3]